A real-world study finds elderly psoriasis patients treated with IL-17 and IL-23 inhibitors achieve comparable long-term ...

Joni Kazantzis didn't think her psoriasis would turn into psoriatic arthritis. But the new diagnosis taught her—and her ...

The following is a summary of “Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients ...

Living with psoriasis presents unique challenges, but with the right skincare routine, you can maintain healthy skin.

Biologics targeting interleukin (IL)-12, IL-23, and IL-17 may have valuable safety benefits among older adults with psoriatic disease, as a lower rate of serious infection was observed among these ...

George Warren, PhD, Lead Author and Principal Scientist at Artelo, said, “We are excited to share the results on this novel target in psoriasis. Our findings demonstrate that ART26.12 has effects ...

Patanjali Ayurved claims a major breakthrough in curing Psoriasis with its herbal medicines Psorogrit and Divya-Taila, as ...

Studies involving multiple aspects of plaque psoriasis evolution, persistence, and progression have produced clues and ...

Substantial savings opportunities exist by using lower-cost biologics for patients with plaque psoriasis, according to one ...

Sanofi’s development of an oral spin on Humira’s mechanism has hit a setback. | Sanofi’s development of an oral spin on ...